Related Experiment Video
Updated: Aug 13, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
Published on: February 1, 2017
Lambda interferon inhibits hepatitis B and C virus replication
Michael D Robek1, Bryan S Boyd, Francis V Chisari
1Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA. michael.robek@yale.edu
Insights
Lambda interferon (IFN-lambda) shows promise for treating chronic hepatitis B and C. This novel interferon effectively inhibits both hepatitis B virus (HBV) and hepatitis C virus (HCV) replication in cell models.
Area of Science:
- Virology
- Immunology
- Hepatology
Background:
- Interferon-lambda (IFN-lambda) activates antiviral responses via a unique receptor.
- Its therapeutic potential against chronic viral hepatitis remains largely unexplored.
Purpose of the Study:
- To investigate the efficacy of IFN-lambda in inhibiting hepatitis B virus (HBV) and hepatitis C virus (HCV) replication.
Main Methods:
- Murine hepatocytes were used to assess HBV replication inhibition.
- Human hepatocyte Huh7 cells were employed to evaluate HCV replicon replication.
Main Results:
- IFN-lambda demonstrated comparable kinetics and efficiency to IFN-alpha/beta in inhibiting HBV replication.
- IFN-lambda effectively blocked replication of both subgenomic and full-length HCV replicons.
Conclusions:
- IFN-lambda exhibits potent antiviral activity against HBV and HCV in vitro.
- These findings suggest IFN-lambda as a potential therapeutic agent for chronic HBV and HCV infections.
Abstract:
Lambda interferon (IFN-lambda) induces an intracellular IFN-alpha/beta-like antiviral response through a receptor complex distinct from the IFN-alpha/beta receptor. We therefore determined the ability of IFN-lambda to inhibit hepatitis B virus (HBV) and hepatitis C virus (HCV) replication. IFN-lambda inhibits HBV replication in a differentiated murine hepatocyte cell line with kinetics and efficiency similar to IFN-alpha/beta and does not require the expression of IFN-alpha/beta or IFN-gamma. Furthermore, IFN-lambda blocked the replication of a subgenomic and a full-length genomic HCV replicon in human hepatocyte Huh7 cells. These results suggest the possibility that IFN-lambda may be therapeutically useful in the treatment of chronic HBV or HCV infection.
Related Concept Videos
Viruses with RNA Genomes
Hepatitis
Inhibitors of Viral Protein Synthesis
Inhibitors Of Virion Release
Viral Hepatitis I: Introduction
Inhibitors of Virion Maturation and Assembly

